スポンサーリンク
Department Of Hematology And Chemotherapy Aichi Cancer Center Hospital | 論文
- Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia
- Acute Promyelocytic Leukemia with Drug-induced Hypersensitivity Syndrome Associated with Epstein-Barr Virus Infection
- Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
- Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
- Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy